Stem-Cell Transplantation
Infliximab shows promise for treatment of gastrointestinal GVHD
Published in Blood Weekly, November 27th, 2003
Acute and chronic GVHD "remain major barriers to successful hematopoietic stem-cell transplantation (SCT)," scientists in the United States noted. "TNF-alpha has been implicated in the pathogenesis of GVHD and TNF-alpha blockade has been explored for treatment of GVHD. The development of a chimeric mouse/human monoclonal antibody (infliximab) which binds to cells producing TNF-alpha, allowing for not only the neutralization of TNF-alpha but also lysis of the cells producing the TNF-alpha, makes this an attractive drug to explore in GVHD."
D.A....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-11-27)
More Articles from Blood Weekly
- Multiple Myeloma
Recombinant erythropoietin enables stem cell autografting without RBC transfusions - Stem-Cell Transplantation
Granulocyte transfusions can prevent post-SCT infections - Hematology
Superparamagnetic labeling enables stromal cell tracking - Multiple Myeloma
Ho-166-DOTMP with stem-cell autografting shows promise against MM in early studies - Multiple Sclerosis
Immunosuppression therapy with stem-cell transplant ineffective in severe progressive MS - AIDS Co-infections
Data: Hepsera associated with sustained reductions in hepatitis B virus - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
